Background Resection of hepatic metastasis from neuroendocrine tumors (NETs) improves quality of life and prolongs 5-year survival. Ablation can be utilized with surgery to achieve complete resection. Although several studies report long-term outcomes for patients undergoing ablation, none have explored perioperative effects of ablation in patients with metastatic NETs. Our goal was to determine if intra-operative ablation during hepatectomy increases risk of adverse outcomes such as surgical site infections (SSIs), bleeding, and bile leak.

Methods A retrospective analysis of the hepatectomy NSQIP database from 2015-2019 was performed to determine the odds of SSIs, bile leaks, or bleeding in patients undergoing intraoperative ablation when compared to hepatectomy alone.

Results Of the 966 patients included in the study, 298(30.9%) underwent ablation during hepatectomy. There were 78(11.7%) patients with SSIs in the hepatectomy alone group and 39(13.1%) patients with a SSIs in the hepatectomy with ablation group. Bile leak occurred in 41(6.2%) and 14(4.8%) patients in the two groups, respectively; bleeding occurred in 117(17.5%) and 33(11.1%), respectively. After controlling for confounding variables, ablation did not increase risk of SSI (p=0.63), bile leak (p=0.34) or bleeding (p=0.07) when compared to patients undergoing resection alone on multivariate analysis.

Conclusions Intraoperative ablation with hepatic resection for NETs is safe in the perioperative period without significant increased risk of infection, bleeding, or bile leak. Surgeons should utilize this modality when appropriate to achieve optimal disease control and outcomes.

The authors have declared no competing interest.

None

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The data is openly available before initiation of this project and can be acquired from NSQIP via appropriate process: https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/participant-use-data-file/participant-use-request-form/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes